Case Report: Torsade de Pointes Induced by the Third-Generation Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor Osimertinib Combined With Litsea Cubeba

Case Report: Torsade de Pointes Induced by the Third-Generation Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor Osimertinib Combined With Litsea Cubeba

Torsades de Pointes (TdP) occurred in a 68-year-old female with epidermal growth factor receptor (EGFR) mutant lung cancer administered osimertinib, the third-generation EGFR tyrosine kinase inhibitor (TKI). Electrocardiogram (ECG) recorded at Tdp showed QT prolongation (QTc = 515 ms), to which a Tr...

Full description

Bibliographic Details
Main Authors: Xia-yan Zhang, Cha-bin Wu, Cai-xia Wu, Li Lin, Yue-juan Zhou, Yan-yan Zhu, Wei-qiang Tian, Song-mei Luo
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
torsade de pointes
osimertinib
Litsea Cubeba
QT prolongation
adverse events
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.903354/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.903354/full

Similar Items